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osting by EAbstract Background: Atropine, an anticholinergic agent, has been shown to increase heart rate
and enhance the sensitivity of dobutamine stress echocardiography in the detection of CAD in
patients with chronotropic incompetence; however, the addition of atropine to exercise stress testing
EST, in these types of patients has not been well studied previously.
Objective: Investigating the usefulness and accuracy of atropine in decreasing the number of incon-
clusive results of EST in patients with chronotropic incompetence and poor exercise capacity.
Methods: Thirty patients (16 males and 14 females with the age range of 40:73 years with mean of
55 ± 8) out of 180 patients who preformed EST were chosen as having chronotropic incompetence
or poor exercise capacity by Borg scale. Atropine was administered during the exercise phase in
doses of 0.5 mg per minute until test conclusion or the maximum dose of 2 mg was reached. All
patients were subjected to stress myocardial perfusion imaging SMPI to conﬁrm accuracy.
Results: Conclusive test results were achieved in 29 patients (97%). Heart rate and blood pressure
were markedly increased with statically highly signiﬁcant difference (P value <0.001), patients on
b-blocker treatment had lower maximum heart rate compared to other patients with signiﬁcant dif-
ference. Twenty-three (79%) patients had negative test results and six (21%) patients had positive4913787.
m (M.M. Khalaf).
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2 M.M. Khalaf et al.test results, and if compared to SMPT results, EST was considered better positive than negative test,
with higher speciﬁcity than sensitivity and accuracy.
Conclusions: Atropine injection during EST signiﬁcantly reduced the inconclusive test results in
patients with chronotropic incompetence and poor exercise capacity.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Exercise stress test (EST) is one of the main diagnostic and
prognostic tests for ischemic heart disease. Exercise testing re-
mains the most widely used test in cardiology for predicting
the likelihood and extent of coronary artery disease, assessing
functional status, and predicting prognosis.1,2
Diagnostic accuracy of exercise testing is inﬂuenced by the
degree of achievement of age-predicted target heart rate3 then
chronotropic incompetence and poor exercise capacity (an
attenuated heart rate response to exercise) limits its utility.
Both of these conditions have been associated with a poor
long-term prognosis and have been shown to be independent
predictors of mortality.4–12
Atropine, an anticholinergic agent, has been shown to in-
crease heart rate and enhance the sensitivity of dobutamine
stress echocardiography in the detection of CAD in patients
with chronotropic incompetence.13,14
At the present time, when a patient is unable to achieve
85% of age-predicted heart rate during EST and has not dem-
onstrated symptoms or electrocardiogram (ECG) changes sug-
gestive of ischemia, the test is labeled as inconclusive. The
patient is generally referred for a pharmacological stress test
(e.g. dobutamine stress echocardiography, adenosine, or dipy-
ridamole nuclear stress testing, cardiac catheterization), which
adds to inconvenience and cost.
For standard exercise electrocardiography (ECG), there
have been few data on atropine injection during or before
physical exercise.15,16 Little information has existed about
how it might be used to decrease the number of inconclusive
tests. It remains to be proven that atropine injection improves
the diagnostic accuracy of standard exercise testing.17
The addition of atropine to standard treadmill testing, in
the presence of chronotropic incompetence or poor exercise
tolerance, has not been well studied previously.
Therefore, the aim of the study was to evaluate the poten-
tial role of atropine in reducing the number of treadmill stress
tests with inconclusive results and minimizing the need for fur-
ther diagnostic tests, also assessing its accuracy.
2. Patients and methods
A prospective, randomized clinical trial was conducted from
September 2009 for a period of 8 months in Multidisciplinary
Unit at the critical care department of Cairo University
Hospital. Out of 180 patients who preformed stress ECG; only
30 patients met the inclusion criteria and enrolled into the
study.
2.1. Inclusion criteria
Thirty patients with chronotropic incompetence and poor
exercise capacity during treadmill stress testing; two criteria
were chosen for the administration of atropine during the test:(1) Patients who had symptoms and an exertion score <7
but do not meet the criteria for termination of the
TMST; we used the non-linear Borg scale for perceived
exertion, with scores ranging from 0 (no exertion at all)
to 10 (very strong exertion).
(2) A heart rate range of 50–75% of the maximum predicted
heart rate (MPHR).2.2. Exclusion criteria
Included standard contraindications for TMST, and condi-
tions that precluded the use of atropine for which each subject
was checked before the test.
All included patients were subjected to the following: full
clinical evaluation; including history and physical examination
with special emphasis on medications and risk factors.
2.3. Study protocol
Treadmill testing was performed according to the modiﬁed
Bruce protocol with continuous 12-lead ECG monitoring.
Patients fasted for at least 4 h before the test, and their
regular medications were not withheld. A patent peripheral
intravenous (IV) line was established in all patients before
the study.
During TMST, patients underwent continuous ECG mon-
itoring and blood pressure measurements every phase during
exercise and every 3 min during the recovery period. Patients
were also questioned every minute during the stress test for
symptoms of chest pain, fatigue, dyspnea, and claudication.
Atropine was administered in doses of 0.5 mg per minute until
the test conclusion (positive test results or target heart rate is
achieved) or until a maximum dose of 2 mg is administered
in the same setting. Patients receiving atropine are monitored
for adverse effects (e.g. irritation at the injection site, dryness
of mouth, tachycardia and palpitations).
All patients were subjected to stress myocardial perfusion
imaging to conﬁrm accuracy.
2.4. Statistical analysis
Patients’ data were tabulated and processed using SPSS (15.0)
statistical package for Windows XP.
Description of quantitative variables as mean, SD and
range.
Description of qualitative variables as number and
percentage.
Chi-square test was used to compare qualitative variables
between groups.
Unpaired t-test was used to compare quantitative variables,
in parametric data (SD < 50% mean).
Paired t-test used to compare quantitative variable in the
same group.
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¼ ability of the test to detectþ ve cases
Specificity ¼ true ve=true veþ falseþ ve
¼ ability of the test to exclude negative cases
PPV ðpositive predictive valueÞ ¼ trueþ =trueþ veþ falseþ v
¼ % of trueþ ve cases to all positive
NPV ¼ true =true veþ false ve
¼ % of the true ve to all negative cases
Accuracy: true +ve + true ve/total.
P value >0.05 insigniﬁcant.
P< 0.05 signiﬁcant.
P< 0.01 highly signiﬁcant.
3. Results
Thirty patients out of 180 were enrolled in the study to take
atropine during stress test as they had an exertion score more
than 7 according to the Borg scale or the MPHR was ranging
from 50% to 75%.
3.1. Demographic data and risk factors
The age range was 40:73 years with mean of 55 ± 8, they were
16 males and 14 females, 60% of them were non-smokers,
63.3% were diabetic and other risk factors’ distribution is seen
in Table 1.
3.2. Medications
Twenty-two patients (73%) of the studied cases were on BB
therapy, while 10% of them were on nitrates.
3.3. Test indications
Twenty-two patients (73%) of the studied cases were presented
for chest pain evaluation, 23% for follow up after percutane-
ous coronary intervention and post-coronary artery bypass
grafting status and 3% for preoperative evaluation.Table 1 Demographic data and risk factors.
Variables Mean ± SD Range
Age (years) 55 ± 8 40–73
Gender
Male 16 53.3%
Female 14 46.7%
Smoking
Smoker 3 10%
Ex-smoker 9 30%
Non-smoker 18 60%
DM 19 63.3%
HTN 11 36.7%
Abnormal cholesterol 14 46.7%
Obesity 9 30%3.4. Atropine dose
The average dose of administered atropine was 0.76 ± 0.34 mg
(18 patients received 0.5 mg, nine patients received 1 mg and
three patients received 1.5 mg). Among study group, more
than 66% of the studied cases (20 patients) had poor physical
ﬁtness, while 33% (10 patients) had chronotropic
incompetence.
3.5. Test outcomes
The heart rate and blood pressure were markedly increased
with statistically highly signiﬁcant difference in between the
stages of stress.
ECG (at rest, just before atropine injection and at peak
exercise), the average change in HR between maximum HR
and HR at the start of injection of atropine was 37% which
has highly signiﬁcant difference, also the heart rate declined
in recovery with statistically highly signiﬁcant difference in
comparison to maximum heart rate by using paired t-test (Ta-
ble 2).
The heart rate increased gradually with atropine dose with
statically highly signiﬁcant difference in between the stages by
using paired t-test, the average change in maximum heart rate
was 86% of the resting heart rate (Table 3).
The HR was markedly increased among BB group from
resting until maximum with statistically highly signiﬁcant dif-
ference in between by using paired t-test. The average change
in maximum heart rate was 90.7% of resting heart rate
(Table 4).
Atropine acted effectively on both groups (BB group and
non-BB group) with no signiﬁcant difference in between both
groups except at a stage of maximum exercise, P value
<0.05 (Table 5).
Conclusive test results were achieved in 29 patients (97%),
only one patient had inconclusive test results 3%. Therefore,
atropine injection resulted in a signiﬁcant decrease in inconclu-
sive test results.
Twenty-three patients (79%) had negative stress test and six
patients (21%) had positive exercise stress test.
Comparison between thallium and stress ECG results
among the studied cases revealed statistically signiﬁcant asso-
ciation between thallium and stress test results by using chi-
square test, P value <0.05 (Table 6).
Stress ECG was considered better positive than negative
test when its results were validated to thallium results specially
in 22 patients coming for chest pain evaluation, with higher
speciﬁcity (100%) than sensitivity (43%) and accuracy (62%)
as the PPV was 100% and NPV was 83% (Table 7).
Follow-up angiographic data were available in only 3 of the
6 patients with positive ECG test results after atropine admin-
istration. The three patients had signiﬁcant CAD. Likewise,
only 1 of the 8 patients with negative stress ECG test results
and positive thallium underwent angiography at our facility
which revealed insigniﬁcant LAD and LCX.3.6. Adverse outcomes of atropine
Ten percent (three patients) of the studied cases had complica-
tions which were prolonged recovery in two patients and ven-
tricular tachycardia with hemodynamic stability in the third
Table 3 Changes in HR at every dose of atropine and at peak
exercise.
Variables Mean ± SD % of change t P value
Resting HR 79 ± 13 – – –
Atropine 0.5 109 ± 9.5 38 13 <0.001
Atropine 1 122 ± 12 54 12 <0.001
Atropine 1.5 127 ± 9 61 10 <0.001
Maximum HR 148 ± 9.8 86 27 <0.001
Table 2 Changes in HR and blood pressure at rest and at peak exercise.
Variables HR at Start of atropine Maximum % of change t P value
HR (bpm) at start of atropine/max 109 ± 9.5 148 ± 9.8 37 3.9 <0.001 HS
HR (bpm) resting/max 79 ± 13 148 ± 9.8 86 27 <0.001 HS
HR (bpm) recovery/max 129 ± 12 147 ± 9 13 11 <0.001 HS
SBP (mmhg) 133 ± 11 162 ± 21 22 7 <0.001 HS
DBP (mmhg) 84 ± 8 91 ± 8 8.3 3 <0.001 HS
Table 4 Changes in HR from resting and after atropine
intake among BB group.
Variables Mean ± SD % of change t P value
Resting HR 76 ± 12 – –
Atropine 0.5 109 ± 10.5 18 3 <0.001
Atropine 1 121 ± 13 60 6 <0.001
Atropine 1.5 121 ± 0 59 8 <0.001
Maximum HR 145 ± 10 90.7 12 <0.001
Table 5 Comparison between BB and non-BB group as
regards changes in HR from resting and after atropine intake.
Variables BB group Non-BB group t P value
Resting HR 76 ± 12 86 ± 11 1.9 >0.05
Atropine 0.5 109 ± 10.5 108 ± 6.6 0.6 >0.05
Atropine 1 121 ± 13 125 ± 7 0.45 >0.05
Atropine 1.5 121 ± 0 – – –
Maximum HR 145 ± 10 153 ± 7 2.2 <0.05
Table 6 Comparison between thallium and stress ECG
among the studied cases.
Stress ECG Negative thallium Positive thallium v2 P
Negative 15 (93.8%) 8 (61.5%) 5.5 <0.05 S
Positive 1 (6.3%) 5 (38.5%)
Table 7 Validity of stress ECG in relation to thallium among
the studied cases and in patients coming for chest pain
evaluation.
Validity % in all
studied patients
(n= 30)
% in chest
pain evaluation
(N= 22)
Sensitivity 40 43
Speciﬁcity 94 100
PPV 83 100
NPV 65 83
Accuracy 68 62
4 M.M. Khalaf et al.patient. None of the previous complications needed hospital
admission; however, they needed 20 min observation.
Palpitation and dry mouth were the most frequent side
effects of atropine which occurred in two patients (6.7%)
and ﬁve patients (16.7%), respectively.4. Discussion
Chronotropic incompetence is deﬁned as a failure to achieve
85% of the age-predicted maximum heart rate at maximum
exercise capacity during stress testing. This phenomenon has
been reported to occur in 11–23% of cases and to be an inde-
pendent predictor of poor outcome.5,15,18
Poor exercise capacity (inability to achieve a moderate level
of exercise), likewise limits the utility of the exercise testing and
is a powerful modiﬁable predictor of adverse outcomes. After
six METs, an increase in each MET of exercise capacity is
associated with a 20–25% decrease in adverse cardiac
outcome.13
The timing of atropine administration in conjunction with
stress testing can be either before the test, as in Variola
et al.15 studies with TMST, or during the test, as in this study.
Pre-test administration of atropine has also been shown to
be useful in exercise echocardiography by increasing peak
heart rate and facilitating better acquisition of post-exercise
images.13
In our study, we administered atropine during EST on the
basis of the patient’s subjective symptoms of near-fatigue so
that we might decrease the incidence of inconclusive test results
and obviate the need for the second stress test used in the study
by Variola et al.15 in his study.
Twenty-ﬁve patients who had inconclusive EST results had
the test repeated with pre-test administration of 1–2 mg of
atropine, 80% of the patients (n= 20) proceeded to have con-
clusive test results. While in our study conclusive test results
were achieved in 29 of the 30 patients (97%) (n= 23), 79%
were negative and (n= 6) 21% were positive. More than
two-third of patients were undergoing the test for evaluation
of chest pain.
In the study conducted by Munagala et al.,17 conclusive test
results were achieved in 23 of the 33 patients (70%): (n= 17)
74% negative and (n= 6) 26% positive. Ghaffari et al.
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(92%) (n= 25) 65% negative and (n= 13) 35% positive.
In the present study, 30 patients received atropine due to
poor exercise capacity (20 patients; 66%) or chronotropic
incompetence (10 patients; 33%) There were no statistically
signiﬁcant differences between subjects with poor exercise
capacity or chronotropic incompetence regarding demographic
data or B blocker usage (P value was not signiﬁcant).
In the study of Munagala et al.,17 33 required atropine due
to poor exercise capacity (six patients; 18%) or chronotropic
incompetence (27 patients; 82%) Atropine administration re-
sulted in conclusive tests more often in subjects with poor
chronotropic response than in subjects with poor exercise
capacity (78% versus 33%, P= 0.001).
In Ghaffari et al. 18 41 patients received atropine due to
poor exercise capacity (nine patients; 22%) or chronotropic
incompetence (32 patients; 78%). There were no differences
in response to atropine in subjects with poor exercise capacity
or chronotropic incompetence. (Inconclusive EST was found
in one patient with poor exercise capacity and two patients
with chronotropic incompetence, P value was not signiﬁcant).
Higher degree of HR increase in our study after atropine
injection (69 beats/min versus 25 beats/min in Munagala
et al.17 study, and 38 beats/min in Ghaffari et al.18 study) that
resulted in more conclusive test results with a lower rate of
atropine injection 0.76 ± 0.34 mg despite highest percentage
of B blocker, may be related to lower resting HR in Munagala
et al.17 study (68 beats/min versus 79 in our study), also higher
incidence of patient with poor physical ﬁtness. We used mod-
iﬁed Bruce protocol instead of Bruce protocol unlike previous
studies as to try to diminish the contribution of test in exhaus-
tion for the patient, which might be the cause for high percent-
age of patients with poor physical ﬁtness. In addition, 30% of
study group was obese, this limiting factor was not commented
upon in previous studies. In addition, the percentage of dia-
betic patients was the highest in our study group we had high-
est mean age.
Myocardial perfusion images were available for all patients
in the study. Angiographic data from only 3 of the 6 patients
with positive ECG test results after atropine administration
were available for review. The three patients had signiﬁcant
CAD. Likewise, only 1 of the 8 patients with negative stress
ECG test results and positive thallium underwent angiography
at our facility which revealed insigniﬁcant LAD and LCX.
Regarding accuracy of atropine in relation to TMST which
was not studied before the present study, it revealed a mean
sensitivity of 40%, mean speciﬁcity of 94% and positive
predictive value of 83%. Moreover, if patients with known
ischemic heart disease were excluded, it demonstrated a mean
sensitivity of 43%, mean speciﬁcity of 100% and positive pre-
dictive value of 100%. These results show that stress ECG is
considered better positive than negative test, with higher spec-
iﬁcity than sensitivity and accuracy. Thus, the use of stress
ECG as a screening test is limited by its low sensitivity. How-
ever, if the result is negative it needs an extra conﬁrmatory test
where these results can be explained by the fact that the study
group consisted of patients with poor exercise capacity and
chronotropic incompetence which in itself is a risk factor.
The addition of atropine administration to TMST would
involve an increase in costs related to establishment of an IV
line, additional personnel for atropine injection, and the cost
of the agent. But considering the higher cost of nuclearimaging, dobutamine echocardiography or coronary angiogra-
phy, it will be a negligible amount.
Even in patients without pre-established IV lines who come
for TMST, we believe the cost and inconvenience of an IV line
may be justiﬁed in selected patients for 2 reasons:
(a) It helps avoid the necessity of a second test performed at
a later time.
(b) It affords additional safety for dealing swiftly with rare
complications of TMST.Conclusion
Atropine injection during EST signiﬁcantly reduced the incon-
clusive test results in patients with chronotropic incompetence
and poor exercise capacity. Stress ECG is considered better
negative than positive test, with higher speciﬁcity than sensitiv-
ity and accuracy. Side effects and complication of atropine use
were minor and did not need hospital admission.References
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